China’s Sinopharm Administers Unproven COVID-19 Vaccine to One Million People Without Any Serious Adverse Event
By HospiMedica International staff writers Posted on 23 Nov 2020 |
Illustration
An untested COVID-19 vaccine developed by China National Pharmaceutical Group Co., Ltd. (Sinopharm Beijing, China) has been administered to almost one million people in the country under the Chinese government’s emergency use scheme without reports of any serious adverse event.
The announcement of one million recipients was made by Liu Jingzhen, chairman of Sinopharm, in a recent interview with a Chinese digital media company. This follows the company’s announcement in September that it had already administered its experimental COVID-19 vaccine to hundreds of thousands of people in China. State officials in China have justified the authorization of an unproven vaccine by claiming that its use is being restricted to high-risk individuals, although this group includes school, supermarket and public transport workers along with frontline health professionals.
Sinopharm’s experimental COVID-19 vaccine uses an inactivated SARS-CoV-2 virus that is unable to replicate in human cells to trigger immune responses. China is still conducting clinical trials of its experimental COVID-19 vaccine candidates in order to test their efficacy and safety. The interim results of the final stage clinical trials of the Chinese vaccines are still to be released, although Jingzhen said that the results would be available soon and the findings were “better than expected”.
“In terms of emergency use, the vaccines were applied to nearly a million people and there has not been a single case of a serious adverse event. People have had only mild symptoms,” said Jingzhen.
Related Links:
China National Pharmaceutical Group Co., Ltd.
The announcement of one million recipients was made by Liu Jingzhen, chairman of Sinopharm, in a recent interview with a Chinese digital media company. This follows the company’s announcement in September that it had already administered its experimental COVID-19 vaccine to hundreds of thousands of people in China. State officials in China have justified the authorization of an unproven vaccine by claiming that its use is being restricted to high-risk individuals, although this group includes school, supermarket and public transport workers along with frontline health professionals.
Sinopharm’s experimental COVID-19 vaccine uses an inactivated SARS-CoV-2 virus that is unable to replicate in human cells to trigger immune responses. China is still conducting clinical trials of its experimental COVID-19 vaccine candidates in order to test their efficacy and safety. The interim results of the final stage clinical trials of the Chinese vaccines are still to be released, although Jingzhen said that the results would be available soon and the findings were “better than expected”.
“In terms of emergency use, the vaccines were applied to nearly a million people and there has not been a single case of a serious adverse event. People have had only mild symptoms,” said Jingzhen.
Related Links:
China National Pharmaceutical Group Co., Ltd.
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans